Open-Label Phase II Study of Neoadjuvant Bevacizumab Combined with FEC→Paclitaxel in Patients with Inflammatory or Locally Advanced Breast Cancer

被引：0
|
作者：
Venturini, M.
Del Mastro, L.
Aitini, E.
Saracchini, S.
Garrone, O.
Durando, A.
De Placido, S.
Boni, C.
Levaggi, A.
Scalamogna, R.
Galli, A.
Clavarezza, M.
机构：
[1] Osped Sacro Cuore Don Calabria, Negrar, VR, Italy
[2] Ist Nazl Ric Canc, Genoa, Italy
[3] Osped C Poma, Mantua, Italy
[4] Osped S Maria Angeli, Pordenone, Italy
[5] Osped Santa Croce & Carle, Cuneo, Italy
[6] Osped S Anna, Turin, Italy
[7] Univ Naples Federico II, Naples, Italy
[8] Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
[9] Med Affairs, Monza, Italy
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P1-11-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-20
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
    Xiujuan Wu
    Peng Tang
    Shifei Li
    Shushu Wang
    Yueyang Liang
    Ling Zhong
    Lin Ren
    Ting Zhang
    Yi Zhang
    Nature Communications, 9
  • [32] A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
    Wu, Xiujuan
    Tang, Peng
    Li, Shifei
    Wang, Shushu
    Liang, Yueyang
    Zhong, Ling
    Ren, Lin
    Zhang, Ting
    Zhang, Yi
    NATURE COMMUNICATIONS, 2018, 9
  • [33] Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
    Wainberg, Zev A.
    Hochster, Howard S.
    Kim, Edward J.
    George, Ben
    Kaylan, Aparna
    Chiorean, E. Gabriela
    Waterhouse, David M.
    Guiterrez, Martin
    Parikh, Aparna
    Jain, Rishi
    Carrizosa, Daniel Ricardo
    Soliman, Hatem H.
    Lila, Thomas
    Reiss, David J.
    Pierce, Daniel W.
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal U.
    Ong, Teng Jin
    O'Dwyer, Peter J.
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4814 - 4822
  • [34] Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study
    Zhou, Liheng
    Xu, Shuguang
    Yin, Wenjin
    Lin, Yanpin
    Du, Yueyao
    Jiang, Yiwei
    Wang, Yaohui
    Zhang, Jie
    Wu, Ziping
    Lu, Jinsong
    ONCOTARGET, 2017, 8 (45) : 79305 - 79314
  • [35] A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+early and locally advanced breast cancer.
    Wu, Jiang
    Cui, Fengqiang
    Yang, Yuqing
    Yu, Jing
    Yang, Jixin
    Wang, Lei
    Xu, Dongdong
    Hu, Wenyu
    Luo, Jialing
    Ma, Wen
    Li, Nanlin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer
    Yardley, Denise A.
    Raefsky, Eric
    Castillo, Raul
    Lahiry, Anup
    LoCicero, Richard
    Thompson, Dana
    Shastry, Mythili
    Burris, Howard A., III
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2011, 11 (05) : 297 - 305
  • [37] ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).
    Grivas, Petros
    Vogelzang, Nicholas J.
    Alva, Ajjai Shivaram
    Feyerabend, Susan
    Loriot, Yohann
    Necchi, Andrea
    Gupta, Sumati
    Josephs, Debra Hannah
    Rodriguez-Vida, Alejo
    Srinivas, Sandy
    Zakharia, Yousef
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Simmons, Andrew
    Nepert, Dale L.
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [38] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A singlearm, open-label, phase II study
    Wang, C.
    Liu, Z.
    Chen, X.
    Qiao, J.
    Li, L.
    Lu, Z.
    Sun, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S436 - S436
  • [39] Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer
    Kosaka, Yoshimasa
    Saeki, Toshiaki
    Takano, Toshimi
    Aruga, Tomoyuki
    Yamashita, Toshinari
    Masuda, Norikazu
    Koibuchi, Yukio
    Osaki, Akihiko
    Watanabe, Junichiro
    Suzuki, Ryu
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2022, 17 : 4567 - 4578
  • [40] Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
    Lavasani, Sayeh Moazami
    Yost, Susan Elaine
    Frankel, Paul Henry
    Ruel, Christopher
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Dan
    Menghi, Francesca
    Liu, Edison T.
    Yeon, Christina Haeyoung
    Yuan, Yuan
    Waisman, James Ross
    Somlo, George
    Mortimer, Joanne E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345